Advertisement
Advertisement
PRTA
Prothena Corporation plc Ordinary Shares
9.30
USDSponsored
-0.29
-3.02%
Jun 02, 13:53 UTC -4
Open
PRTA Earnings Reports
Positive Surprise Ratio
PRTA beat 20 of 41 last estimates.
49%
Next Report
Date of Next Report
Aug 03, 2026
Estimate for Q2 26 (Revenue/ EPS)
$43.96M
/-$0.12
Implied change from Q1 26 (Revenue/ EPS)
-13.95%
/-119.67%
Implied change from Q2 25 (Revenue/ EPS)
+894.50%
/-93.06%
Prothena Corporation plc Ordinary Shares earnings per share and revenue
On May 07, 2026, PRTA reported earnings of 0.61 USD per share (EPS) for Q1 26, beating the estimate of -0.35 USD, resulting in a 271.69% surprise. Revenue reached 51.08 million, compared to an expected 1.03 million, with a 4858.65% difference. The market reacted with a +2.00% price change (close before vs. close after earnings).
Looking ahead to Q2 26, 4 analysts forecast an EPS of -0.12 USD, with revenue projected to reach 43.96 million USD, implying an decrease of -119.67% EPS, and decrease of -13.95% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Greenwich LifeSciences, Inc.
Report Date
Jun 01, 2026 For Q4 25
Estimate
-$0.32
Actual
-$0.57
Surprise
-77.70%
Connect Biopharma Holdings Limited Ordinary Shares
Report Date
May 22, 2026 For Q1 26
Estimate
-$1.53
Actual
-$2.35
Surprise
-53.05%
Scilex Holding Company Common Stock
Report Date
May 20, 2026 For Q1 26
Estimate
-Actual
-$4.76
Surprise
-
Roivant Sciences Ltd. Common Shares
Report Date
May 20, 2026 For Q4 26
Estimate
-$0.35
Actual
-$0.57
Surprise
-64.63%
Belite Bio, Inc - ADR
Report Date
May 20, 2026 For Q1 26
Estimate
-$0.64
Actual
-$0.68
Surprise
-4.87%
Immunovant, Inc. Common Stock
Report Date
May 20, 2026 For Q4 26
Estimate
-$0.61
Actual
-$0.73
Surprise
-19.11%
Akari Therapeutics plc ADR (0.01 USD)
Report Date
May 19, 2026 For Q1 26
Estimate
-$1.40
Actual
-$1.57
Surprise
-11.81%
EVOGENE LTD.
Report Date
May 20, 2026 For Q1 26
Estimate
-$0.27
Actual
-$0.60
Surprise
-117.86%
FAQ
What were Prothena Corporation plc Ordinary Shares's earnings and revenue for the latest quarter Q1 2026?
For Q1 2026, Prothena Corporation plc Ordinary Shares reported EPS of $0.61, beating estimates by 271.69%, and revenue of $51.08M, 4858.65% above expectations.
How did the market react to Prothena Corporation plc Ordinary Shares's Q1 2026 earnings?
The stock price moved up 2%, changed from $10.52 before the earnings release to $10.73 the day after.
When is Prothena Corporation plc Ordinary Shares expected to report next?
The next earning report is scheduled for Aug 03, 2026.
What are the forecasts for Prothena Corporation plc Ordinary Shares's next earnings report?
Based on 4
analysts, Prothena Corporation plc Ordinary Shares is expected to report EPS of -$0.12 and revenue of $43.96M for Q2 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement